Elite Pharmaceuticals (OTCMKTS:ELTP) Trading Up 6.1% – Should You Buy?
by Scott Moore · The Cerbat GemElite Pharmaceuticals Inc. (OTCMKTS:ELTP – Get Free Report)’s stock price shot up 6.1% during mid-day trading on Friday . The company traded as high as $0.5142 and last traded at $0.5140. 1,012,728 shares traded hands during trading, a decline of 13% from the average session volume of 1,158,794 shares. The stock had previously closed at $0.4845.
Elite Pharmaceuticals Trading Up 1.7%
The company has a debt-to-equity ratio of 0.06, a current ratio of 8.04 and a quick ratio of 6.34. The business’s 50-day simple moving average is $0.56 and its two-hundred day simple moving average is $0.60. The stock has a market capitalization of $529.51 million, a price-to-earnings ratio of 49.33 and a beta of 0.29.
About Elite Pharmaceuticals
Elite Pharmaceuticals, Inc is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care.
Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities.